Bolt Biotherapeutics Stock

boltbio.comHealthcareFounded: 2015Funding to Date: $64.6MM

Bolt Biotherapeutics is a biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients.

Register for Details

For more details on financing and valuation for Bolt Biotherapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Bolt Biotherapeutics.

Register Today

Team

Management Team

Chih-Ping Liu Ph.D
Co-Founder & President
Randall Schatzman Ph.D
Chief Executive Officer & Board Member
Edgar Engleman
Co-Founder & Board Member
Grant Yonehiro
Chief Business Officer & Chief Operating Officer

Board Members

Ashish Khanna Ph.D
NFLS - Pivotal
Randall Schatzman Ph.D
Edgar Engleman
Peter Moldt
Richard Miller MD
Ken Harrison
Peter Bisgaard
Mahendra Shah

Other companies like Bolt Biotherapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$885.01MM

News

/PRNewswire/ -- Bolt Biotherapeutics, Inc., a private biotechnology company focused on using its Immune-Stimulating Antibody Conjugate (ISAC) platform...
Bolt Biotherapeutics, founded by Stanford immuno-oncology veteran Edgar Engleman, is developing new class of cancer drugs called immune stimulating antibody conjugates. Backed by fresh data from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator, the company is preparing a phase 1 trial.
In cancer lingo, “cold” tumors are cancers that the immune system doesn’t recognize or respond to, even when immune-stimulating drugs are given. Bolt